Becton, Dickinson and Company (NYSE:BDX) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Becton, Dickinson and Company (NYSE:BDX) issued its earnings results on Thursday. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04, RTT News reports. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the company earned $3.42 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year. Becton, Dickinson and Company updated its FY 2025 guidance to 14.250-14.600 EPS and its FY25 guidance to $14.25-14.60 EPS.

Becton, Dickinson and Company Trading Up 2.0 %

Shares of BDX opened at $231.65 on Friday. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $249.89. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The firm’s 50-day moving average price is $237.04 and its 200-day moving average price is $235.09. The firm has a market capitalization of $66.96 billion, a price-to-earnings ratio of 39.00, a PEG ratio of 1.76 and a beta of 0.43.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 1.80%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 70.03%.

Analysts Set New Price Targets

BDX has been the topic of several analyst reports. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James lowered their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI upped their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.